RT Journal Article
T1 Capsule endoscopy in young patients with iron deficiency anaemia and negative bidirectional gastrointestinal endoscopy.
A1 Yung, Diana E
A1 Rondonotti, Emanuele
A1 Giannakou, Andry
A1 Avni, Tomer
A1 Rosa, Bruno
A1 Toth, Ervin
A1 Lucendo, Alfredo J
A1 Sidhu, Reena
A1 Beaumont, Hanneke
A1 Ellul, Pierre
A1 Negreanu, Lucian
A1 Jiménez-Garcia, Victoria Alejandra
A1 McNamara, Deidre
A1 Kopylov, Uri
A1 Elli, Luca
A1 Triantafyllou, Konstantinos
A1 Shibli, Fahmi
A1 Riccioni, Maria Elena
A1 Bruno, Mauro
A1 Dray, Xavier
A1 Plevris, John N
A1 Koulaouzidis, A
A1 And the Capsule Endoscopy in Young Patients with IDA research group, 
A1 Argüelles-Arias, Federico
A1 Becq, Aymeric
A1 Branchi, Federica
A1 Tejero-Bustos, María Ángeles
A1 Cotter, Jose
A1 Eliakim, Rami
A1 Ferretti, Francesca
A1 Gralnek, Ian M
A1 Herrerias-Gutierrez, Juan Manuel
A1 Hussey, Mary
A1 Jacobs, Maarten
A1 Johansson, Gabriele Wurm
A1 McAlindon, Mark
A1 Montiero, Sara
A1 Nemeth, Artur
A1 Pennazio, Marco
A1 Rattehalli, Deepa
A1 Stemate, Ana
A1 Tortora, Annalisa
A1 Tziatzios, Georgios
K1 Capsule endoscopy
K1 iron deficiency anaemia
K1 neoplasia
K1 small bowel
K1 young
AB Recent data imply young patients (age ≤50 years) undergoing small-bowel (SB) capsule endoscopy (CE) for iron deficiency anaemia (IDA) show higher diagnostic yield (DY) for sinister pathology. We aimed to investigate DY of CE in a large cohort of young IDA patients, and evaluate factors predicting significant SB pathology. This was a retrospective, multicentre study (2010-2015) in consecutive, young patients (≤50 years) from 18 centres/12 countries, with negative bidirectional gastrointestinal (GI) endoscopy undergoing SBCE for IDA. Exclusion criteria: previous/ongoing obscure-overt GI bleeding; age 50 years; comorbidities associated with IDA. Data retrieved: SBCE indications; prior investigations; medications; SBCE findings; final diagnosis. Clinical and laboratory data were analysed by multivariate logistic regression. Data on 389 young IDA patients were retrieved. In total, 169 (43.4%) were excluded due to incomplete clinical data; data from 220 (122F/98M; mean age 40.5 ± 8.6 years) patients were analysed. Some 71 patients had at least one clinically significant SBCE finding (DY: 32.3%). They were divided into two groups: neoplastic pathology (10/220; 4.5%), and non-neoplastic but clinically significant pathology (61/220; 27.7%). The most common significant but non-neoplastic pathologies were angioectasias (22/61) and Crohn's disease (15/61). On multivariate analysis, weight loss and lower mean corpuscular volume(MCV) were associated with significant SB pathology (OR: 3.87; 95%CI: 1.3-11.3; p = 0.01; and OR: 0.96; 95%CI: 0.92-0.99; p = 0.03; respectively). Our model also demonstrates association between use of antiplatelets and significant SB pathology, although due to the small number of patients, definitive conclusions cannot be drawn. In IDA patients ≤50 years with negative bidirectional GI endoscopy, overall DY of SBCE for clinically significant findings was 32.3%. Some 5% of our cohort was diagnosed with SB neoplasia; lower MCV or weight loss were associated with higher DY for SB pathology.
SN 2050-6406
YR 2017
FD 2017-02-01
LK http://hdl.handle.net/10668/11831
UL http://hdl.handle.net/10668/11831
LA en
DS RISalud
RD Apr 7, 2025